Adrenocortical carcinoma secondary prevention: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
No edit summary |
||
| Line 1: | Line 1: | ||
__NOTOC__ | |||
{{Adrenocortical carcinoma}} | {{Adrenocortical carcinoma}} | ||
{{CMG}} | {{CMG}}; {{AE}} {{MAD}} | ||
==Overview== | ==Overview== | ||
| Line 6: | Line 7: | ||
== Adrenocortical carcinoma secondary prevention == | == Adrenocortical carcinoma secondary prevention == | ||
*Patients should be followed at 3-month intervals after initial treatment for 2 to 3 years. | *Patients should be followed at 3-month intervals after initial treatment for 2 to 3 years. | ||
*Surveillance intervals may be increased to 6 months for the next 5 years. | *Surveillance intervals may be increased to 6 months for the next 5 years. | ||
*Surveillance should also include: | *Surveillance should also include: | ||
**[[Cross-sectional]] [[imaging]] of [[chest]], [[abdomen]], and [[pelvis]] | **[[Cross-sectional]] [[imaging]] of [[chest]], [[abdomen]], and [[pelvis]] | ||
| Line 14: | Line 13: | ||
**Laboratory evaluation for [[steroid hormones]] | **Laboratory evaluation for [[steroid hormones]] | ||
**Evaluation of side effects is also important in case of [[adjuvant]] [[mitotane]] [[therapy]] | **Evaluation of side effects is also important in case of [[adjuvant]] [[mitotane]] [[therapy]] | ||
==References== | ==References== | ||
{{reflist|2}} | {{reflist|2}} | ||
Revision as of 17:16, 3 October 2017
|
Adrenocortical carcinoma Microchapters |
|
Differentiating Adrenocortical carcinoma from other Diseases |
|---|
|
Diagnosis |
|
Treatment |
|
Case Study |
|
Adrenocortical carcinoma secondary prevention On the Web |
|
American Roentgen Ray Society Images of Adrenocortical carcinoma secondary prevention |
|
Risk calculators and risk factors for Adrenocortical carcinoma secondary prevention |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Mohammed Abdelwahed M.D[2]
Overview
Adrenocortical carcinoma secondary prevention
- Patients should be followed at 3-month intervals after initial treatment for 2 to 3 years.
- Surveillance intervals may be increased to 6 months for the next 5 years.
- Surveillance should also include: